ArticleGenome biology2019
Collateral damage: benchmarking off-target effects in genome editing.
Article in Genome biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients.Blood advances · 2025Review
- Investigating impacts of the mycothiazole chemotype as a chemical probe for the study of mitochondrial function and aging.GeroScience · 2024Article
- Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing.Nucleic acids research · 2024Article
- Article
- RNA in Therapeutics: CRISPR in the Clinic.Molecules and cells · 2023Review
- Programmable RNA editing with endogenous ADAR enzymes - a feasible option for the treatment of inherited retinal disease?Frontiers in molecular neuroscience · 2023Review
- Fitness effects of CRISPR endonucleases ineLife · 2022Article
- Breeding for disease resilience: opportunities to manage polymicrobial challenge and improve commercial performance in the pig industry.CABI agriculture and bioscience · 2022Review
- Article
- Development of CRISPR/Cas9 system for targeted DNA modifications and recent improvements in modification efficiency and specificity.BMB reports · 2020Review
- A roadmap for neurodevelopmental disease modeling for non-stem cell biologists.Stem cells translational medicine · 2020Review
- The clinical potential of gene editing as a tool to engineer cell-based therapeutics.Clinical and translational medicine · 2020Review
- CRISPR off-targets: a question of context.Cell biology and toxicology · 2020Article
- RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences.International journal of molecular sciences · 2020Review
- A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.Frontiers in genome editing · 2020Review
- Targeted Gene Delivery: Where to Land.Frontiers in genome editing · 2020Review
- Plant Biosystems Design Research Roadmap 1.0.Biodesign research · 2020Review
- WeReview: CRISPR Tools-Live Repository of Computational Tools for Assisting CRISPR/Cas Experiments.Bioengineering (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
This editorial discusses what levels of off-target effects can be tolerated in genome editing, in the context of various types of applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.